Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.64 |
| ▸ | HTR2C | P28335 | 14/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623988 | 0.96 | HTR2A (0.59) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4623472 | 0.94 | HTR2A (0.55) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4877632 | 0.91 | HTR2A (0.51) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4876612 | 0.91 | HTR2A (0.51) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4885411 | 0.91 | HTR2A (0.50) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4623498 | 0.90 | MEN1 (0.52) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4622291 | 0.90 | ACVR1 (0.55) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4884847 | 0.90 | HTR2A (0.49) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4621383 | 0.89 | HTR2A (0.49) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL14020253 | 0.89 | MEN1 (0.55) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | GILEAD SCIENCES, INC. | 2010-04-22 | — | — | US | disclosed |
| EP-2125841-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND BETA-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | Gilead Sciences, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| WO-2008076265-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND β-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1904479-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006926-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | HTR2A 3453/4885HTR2C 3934/4885L3MBTL1 4039/4885 |
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | ADRB1, ADRB2, PDE11A | HTR2A 952/4885HTR2C 1265/4885L3MBTL1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.